WVE vs TMO vs ILMN vs PACB

For growth investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus -60. 5% for Wave Life Sciences Ltd. (WVE). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 8x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Wave Life Sciences Ltd. (WVE) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Thermo Fisher Scientific Inc.

(TMO) is the cheapest at 26. 8x versus Illumina, Inc. at 30. 5x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Illumina, Inc. wins at 7. 52x versus Thermo Fisher Scientific Inc. 's 9. 06x.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +3. 8%, compared to -95. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: TMO returned +223. 2% versus PACB's -86. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 0. 95β versus Pacific Biosciences of California, Inc. 's 2. 92β — meaning PACB is approximately 207% more volatile than TMO relative to the S&P 500. On balance sheet safety, Wave Life Sciences Ltd. (WVE) carries a lower debt/equity ratio of 3% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Thermo Fisher Scientific Inc.

(TMO) is pulling ahead at 3. 9% versus -60. 5% for Wave Life Sciences Ltd. (WVE). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -72. 9% for Wave Life Sciences Ltd.. Over a 3-year CAGR, WVE leads at 127. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -478. 3% for Wave Life Sciences Ltd. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -504. 1% for WVE. At the gross margin level — before operating expenses — WVE leads at 79. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Illumina, Inc. (ILMN) is the more undervalued stock at a PEG of 7. 52x versus Thermo Fisher Scientific Inc. 's 9. 06x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 1x forward P/E versus 31. 8x for Illumina, Inc. — 12. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WVE: 354. 0% to $26. 38.

In this comparison, TMO (0.

4% yield) pays a dividend. WVE, ILMN, PACB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), +223. 2% 10Y return). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMO: +223. 2%, PACB: -86. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.